Holen Sie sich die Stockscreener-App
37.86
0.03%
-0.010
Handel nachbörslich:
38.35
0.49
+1.29%
Schlusskurs vom Vortag:
$37.87
Offen:
$37.89
24-Stunden-Volumen:
450.49K
Relative Volume:
1.41
Marktkapitalisierung:
$1.19B
Einnahmen:
$566.77M
Nettoeinkommen (Verlust:
$48.16M
KGV:
31.82
EPS:
1.19
Netto-Cashflow:
$274.29M
1W Leistung:
+27.26%
1M Leistung:
+16.42%
6M Leistung:
+22.21%
1J Leistung:
+3.13%
1-Tages-Spanne:
$37.68
$38.23
1-Wochen-Bereich:
$31.40
$38.23
52-Wochen-Spanne:
$23.23
$42.29
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
Firmenname
Collegium Pharmaceutical Inc
Sektor
Telefon
781-713-3699
Adresse
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Vergleichen Sie COLL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COLL
Collegium Pharmaceutical Inc
|
37.86 | 1.19B | 566.77M | 48.16M | 274.29M | 1.19 |
|
ZTS
Zoetis Inc
|
152.44 | 66.38B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 46.20B | 29.96B | 957.25M | 5.31B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.69 | 42.99B | 14.26B | 1.98B | 0 | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 19.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
309.72 | 13.63B | 2.99B | 1.21B | 1.13B | 25.06 |
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Hochstufung | Needham | Hold → Buy |
| 2024-07-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-06-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-05-10 | Herabstufung | Needham | Buy → Hold |
| 2024-05-10 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-01-04 | Herabstufung | Jefferies | Buy → Hold |
| 2023-08-25 | Bestätigt | Needham | Buy |
| 2023-05-02 | Fortgesetzt | Jefferies | Buy |
| 2022-08-08 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-02-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-14 | Eingeleitet | BWS Financial | Sell |
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-19 | Fortgesetzt | Jefferies | Buy |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-03 | Fortgesetzt | H.C. Wainwright | Buy |
| 2019-04-12 | Fortgesetzt | Janney | Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2019-01-16 | Bestätigt | Needham | Buy |
| 2018-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2018-02-07 | Bestätigt | Needham | Buy |
| 2017-12-05 | Bestätigt | Needham | Buy |
| 2017-09-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-05-11 | Bestätigt | Needham | Buy |
| 2016-09-13 | Eingeleitet | Gabelli & Co | Buy |
| 2015-06-01 | Eingeleitet | Jefferies | Buy |
| 2015-06-01 | Eingeleitet | Needham | Buy |
| 2015-06-01 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Collegium Pharmaceutical Inc Aktie (COLL) Neueste Nachrichten
IBD Rating Upgrades: Collegium Pharmaceutical Flashes Improved Relative Price Strength - MSN
Collegium Pharmaceutical (NASDAQ:COLL) Upgraded at HC Wainwright - MarketBeat
COLL Q2 Deep Dive: Jornay Expansion Drives Revenue Guidance Increase, Margins Face Investment Pressure - Yahoo Finance
Collegium Pharmaceutical Shows Market Leadership With Jump To 81 RS Rating - Investor's Business Daily
H.C. Wainwright assumes coverage on Collegium Pharmaceutical stock with Buy rating - Investing.com Canada
Collegium Pharmaceutical (COLL) Is Up 16.2% After Raising 2025 Revenue Guidance on Strong Q2 Results - simplywall.st
Collegium Pharmaceutical Earns Membership In 95-Plus Composite Rating Club - Investor's Business Daily
Collegium Pharmaceutical's Q2 2025: Key Contradictions on Jornay PM Sales Estimates and Pain Portfolio Competition - AInvest
Collegium Pharmaceutical (NASDAQ:COLL) Upgraded by Wall Street Zen to Strong-Buy Rating - MarketBeat
Collegium Pharmaceutical Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Compared to Estimates, Collegium Pharmaceutical (COLL) Q2 Earnings: A Look at Key Metrics - MSN
Collegium Pharmaceutical Reports Record Q2 2025 Revenue, Raises Outlook and Initiates $150M Share Repurchase Program - AInvest
Collegium Pharmaceutical Inc. Attempts Reversal From Key SupportWeekly Stock Opportunity Radar Scanner Activated - beatles.ru
Why Collegium Pharmaceutical (COLL) Rose 10.3% After Raising 2025 Revenue Guidance Despite Lower Earnings - simplywall.st
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q2 2025 Earnings Call Transcript - Insider Monkey
Collegium Pharmaceutical: Q2 Earnings Snapshot - Greenwich Time
Collegium Pharmaceutical Inc (COLL) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Collegium Pharmaceutical Reports Strong Q2 2025 Results - TipRanks
Collegium Pharmaceuticals Reports Strong Earnings and Growth - TipRanks
Truist Securities raises Collegium Pharmaceutical stock price target to $45 By Investing.com - Investing.com Australia
Collegium Pharmaceutical’s Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating - TipRanks
Collegium Pharmaceutical Exceeds Q2 Expectations, Reporting 29.4% YoY Revenue Growth and a 10.2% Stock Jump. - AInvest
Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q2 Expectations, Stock Jumps 10.2% - Yahoo Finance
Collegium raises 2025 revenue guidance to $760M as Jornay PM growth accelerates - MSN
Collegium Pharmaceutical Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Collegium Pharmaceutical Q2 2025 slides: Revenue surges 29%, guidance raised - Investing.com
Collegium Pharmaceutical Q2 2025 slides: Revenue surges 29%, guidance raised By Investing.com - Investing.com South Africa
Transcript : Collegium Pharmaceutical, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates - sharewise.com
SIXS ETF Implied Analyst Target Price: $58.24 - AInvest
Collegium Pharmaceutical Reports Record Q2 2025 Revenue - TipRanks
Collegium Pharmaceutical earnings beat by $0.02, revenue topped estimates - Investing.com Canada
Collegium Pharma Q2 Revenue Surpasses Expectations, Initiates $150 Million Share Buyback Plan - AInvest
Earnings Flash (COLL) Collegium Pharmaceutical, Inc. Reports Q2 Revenue $188.0M, vs. FactSet Est of $180.9M - MarketScreener
Earnings Flash (COLL) Collegium Pharmaceutical, Inc. Posts Q2 Adjusted EPS $1.68 per Share, vs. FactSet Est of $1.62 - MarketScreener
Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook - GlobeNewswire
Collegium Pharmaceutical to report Q2 2025 financial results on August 7, 2025. - AInvest
Collegium Pharmaceutical Q2 Earnings: Revenue Expected to Grow 24.2% YoY - AInvest
Collegium Pharmaceutical (COLL) Q2 Earnings: What To Expect - Yahoo Finance
Collegium Pharmaceutical is helping individuals with ADHD - KOIN.com
Collegium Pharmaceuticals is helping those with ADHD - KOIN.com
Moving Average Crossover Confirms Uptrend in Collegium Pharmaceutical Inc.Breakout Momentum Picks With Protection Outlined - metal.it
Collegium Pharmaceutical Inc. Rebound Backed by Sentiment ShiftLow Risk High Return Opportunities Identified - metal.it
Real Time Chart Alerts Flash Bullish on Collegium Pharmaceutical Inc.Trade Ready Stock Watch for Short Term Published - metal.it
When is Collegium Pharmaceutical Inc. stock expected to show significant growthInvest smarter with comprehensive market analysis - Jammu Links News
Does Collegium Pharmaceutical Inc. stock perform well during market downturnsCapitalize on high-yield stocks early - Jammu Links News
What makes Collegium Pharmaceutical Inc. stock price move sharplyCapitalize on emerging growth stocks - Jammu Links News
Is Collegium Pharmaceutical Inc. stock overvalued or undervaluedGet insider insights into market trends - Jammu Links News
What is the risk reward ratio of investing in Collegium Pharmaceutical Inc. stockUnlock powerful stock screening for profits - Jammu Links News
What catalysts could drive Collegium Pharmaceutical Inc. stock higher in 2025Capitalize on market momentum for profits - Jammu Links News
What are Collegium Pharmaceutical Inc. company’s key revenue driversAccess powerful market insights for free - Jammu Links News
Finanzdaten der Collegium Pharmaceutical Inc-Aktie (COLL)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):